Navigation Links
Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
Date:12/26/2007

NEW YORK, Dec. 26 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that it is working with clinical investigators at the South African site where a safety study is in progress for pafuramidine (DB289), an investigational therapy. In preliminary findings from the study, abnormal laboratory values were found in several volunteers following treatment with pafuramidine. The Company has discussed the preliminary findings with the US Food and Drug Administration (USFDA), and as a precautionary measure the pafuramidine program has been placed on clinical hold.

In this South African safety study volunteers were dosed with pafuramidine 100 mg twice daily for 14 days or placebo. The subjects are undergoing close monitoring for any changes in the status of their liver function. No subject has required any treatment or hospitalization for the abnormalities to date.

The Company's Chairman and Chief Executive Officer Eric L. Sorkin stated, "Our primary concern is the safety of the patients. We are working closely with experts and the Data Safety Monitoring Board for pafuramidine."

Carol Olson, M.D., Ph.D., Senior Vice President of Pharmaceutical Development and Chief Officer of Immtech, stated, "This evaluation will continue until patients stabilize or return to baseline status. At that time, Immtech and the independent experts in liver toxicity will prepare a summary of the available safety data and recommendations for presentation to the FDA. The clinical hold may be released after FDA has received satisfactory data regarding the safety of pafuramidine."

This South African study involving healthy volunteers is being conducted to collect additional safety data regarding pafuramidine to supp
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Immtech Completes Malaria Prevention Trial
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a gymnastics ... 12 years of age that offers everything from gymnastics, dance, ... Camps, is now under new ownership. , Kevin Berry comes ... over six years at The Little Gym of Bellaire in ... has over ten years of experience working with children, including ...
(Date:7/13/2014)... 2014 Max International has ... will be the featured guest at its Charity Exhibition ... Rico. Attendees will learn about Max’s health products ... exhibition basketball games and perform in a 3 point ... health- and energy-boosting supplements , has recently announced former ...
(Date:7/13/2014)... device developed at Cedars-Sinai can provide early detection ... and are a classic sign of Alzheimer,s disease, ... clinical trial in Australia. , The researchers will ... presentation at the Alzheimer,s Association International Conference 2014 ... conference organizers to participate in a "breaking news" ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 A ... Wright & Schulte LLC to provide consumers with the ... sometimes accompany use of the blood-thinning medication, as well ... pending in courts around the country. The law ... who may have suffered from life-threatening internal bleeding and ...
(Date:7/13/2014)... Ann Arbor, MI (PRWEB) July 13, 2014 ... online learning program he has just launched at http://www.HealthYourself101.com ... management of visceral obesity. , Power has set out ... and its ill effects that’s actually – dare we say ... , “The program,” says Power, “aims to engage the remote ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... to treat injury, stroke and even Alzheimer,s, experts say , , ... study involving mice suggests the brain,s own stem cells may ... These neural stem cells work by protecting existing cells and ... the University of California, Irvine, were able to bring the ...
... As the seventh leading cause of cancer death worldwide, ... ethnic group and gender. Esophageal cancer is thought to ... interact with the host genome. Researchers have long been ... been conducted on gene-environment interaction and gene polymorphisms for ...
... remove part or all of the colon (colectomy) for people ... researchers in a study published on bmj.com today. ... of the intestine and includes ulcerative colitis and Crohns disease. ... are affected and many people will require colectomy at some ...
... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ), ... of a Phase 2a clinical trial evaluating,MAP0005 ... chronic obstructive,pulmonary disease (COPD). MAP0005 is ... long-acting,beta2-agonist delivered to the respiratory tract using ...
... BPUR ) announced today that the trading symbol for ... BPUR at the open of the market on,Wednesday, October ... revert to the following ticker symbols: BPREW reverting to ... Biopure Corporation Biopure Corporation develops, manufactures and ...
... HRAL) announced today that it has formed an alliance ... Stores (NYSE: WMT ) to help,conquer hearing loss ... Starting November 15, 2007, HearAtLast customers will receive a,$100.00 ... with,their American Express card. The promotion is scheduled to ...
Cached Medicine News:Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Threshold for bowel surgery may be too high, warn experts 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 3Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 4
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... 6, 2012   Heska Corporation (NASDAQ: ... and other specialty veterinary products , today announced that ... practices research, tools and metrics for patent analysis and ... Heska,s Science Strength in the top 50 of the ...
...  The United States Patent & Trademark Office (USPTO) has ... ) that the USPTO has rejected all claims by ... 7,357,891 (the ,891 Patent) which is currently being asserted ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ...
Cached Medicine Technology:The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 2The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 3US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 2US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 3
... SET LNOP Blue Sensor is the first ... The LNOP Blue sensor is the first ... for cyanotic infants and children. Cyanotic ... conditions for reliable and accurate pulse oximetry, ...
Inquire...
... The Trinity Biotech Captia™ Varicella- Zoster ... (ELISA) is intended for the detection and ... in human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
ELISA kit for Varicella-zoster IgG....
Medicine Products: